Overexpression of SETDB1 was detected in prostate cancer in clinical and preclinical studies, and the cancer phenotype was suppressed by siRNA in SETDB1 knockdown cells (Sun et al., 2014). This evidence concerns the gene SETDB1 and prostate carcinoma.